← All trials
NCT05165303
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2022
- Primary completion
- Jun 28, 2022
- Completion date
- Jul 30, 2022
- First posted
- Dec 21, 2021
- Last posted
- Dec 21, 2021
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Imam Abdulrahman Bin Faisal UniversityLead sponsor
- Imam Abdulrahman Bin Faisal UniversityReponsible party - principal investigator
- King Fahd university hospitalStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.